David M. Bowen

4.1k total citations · 1 hit paper
53 papers, 3.2k citations indexed

About

David M. Bowen is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Physiology. According to data from OpenAlex, David M. Bowen has authored 53 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cellular and Molecular Neuroscience, 17 papers in Molecular Biology and 17 papers in Physiology. Recurrent topics in David M. Bowen's work include Neuroscience and Neuropharmacology Research (19 papers), Cholinesterase and Neurodegenerative Diseases (12 papers) and Alzheimer's disease research and treatments (11 papers). David M. Bowen is often cited by papers focused on Neuroscience and Neuropharmacology Research (19 papers), Cholinesterase and Neurodegenerative Diseases (12 papers) and Alzheimer's disease research and treatments (11 papers). David M. Bowen collaborates with scholars based in United Kingdom, United States and Mexico. David M. Bowen's co-authors include Alan Davison, Carolyn Beebe Smith, Paul T. Francis, Pamela White, Alan M. Palmer, Andrew Procter, Gary C. Stratmann, Margaret M. Esiri, Neil R. Sims and Norman S. Radin and has published in prestigious journals such as Nature, New England Journal of Medicine and Brain.

In The Last Decade

David M. Bowen

53 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES

1976 977 citations David M. Bowen et al. profile →

Peers

Countries citing papers authored by David M. Bowen

Since Specialization

Citations

This map shows the geographic impact of David M. Bowen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Bowen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Bowen more than expected).

Fields of papers citing papers by David M. Bowen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Bowen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Bowen. The network helps show where David M. Bowen may publish in the future.

Co-authorship network of co-authors of David M. Bowen

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Bowen. A scholar is included among the top collaborators of David M. Bowen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Bowen. David M. Bowen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Simplifying complex sequence information: A PCP-consensus protein binds antibodies against all four Dengue serotypes 2012 ·Vaccine ·David M. Bowen, (unknown), Wenzhe Lu, Catherine H. Schein	13
2	6. The cholinergic system and the excitatory amino acids in Alzheimer's disease 2009 ·Acta Neurologica Scandinavica ·David M. Bowen	1
3	New Approaches to Imaging Based on Effects of Neurotoxins 1997 ·Dementia and Geriatric Cognitive Disorders ·Paul T. Francis, Iain P. Chessell, David M. Bowen	2
4	Presynaptic Serotonergic Markers in Community‐Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication 1996 ·Journal of Neurochemistry ·Christopher Chen, Janet Alder, David M. Bowen, Margaret M. Esiri, Brendan McDonald, Tony Hope, Kim A. Jobst, Paul T. Francis	115
5	Cholinomimetics Increase Glutamate Outflow via an Action on the Corticostriatal Pathway: Implications for Alzheimer's Disease 1995 ·Journal of Neurochemistry ·(unknown), Paul T. Francis, Gary C. Stratmann, David M. Bowen	37
6	Increased transmitter amino acid concentration in human ventricular CSF after brain trauma 1994 ·Neuroreport ·Alan M. Palmer, Donald W. Marion, (unknown), David M. Bowen, Steven T. DeKosky	120
7	The Effects of Alzheimer's Disease, Other Dementias, and Premortem Course on β‐Amyloid Precursor Protein Messenger RNA in Frontal Cortex 1994 ·Journal of Neurochemistry ·Paul J. Harrison, A.J.L. Barton, Andrew Procter, David M. Bowen, R.C.A. Pearson	29
8	Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives 1993 ·Journal of Neurochemistry ·Paul T. Francis, Neil R. Sims, Andrew Procter, David M. Bowen	191
9	Effect of Li+ therapy and site of origin on cerebrospinal fluid β-amyloid precursor protein derivatives 1993 ·Biochemical Society Transactions ·(unknown), Andrew Procter, Marie-Thérèse Webster, Paul T. Francis, Andrew Hodgkiss, David M. Bowen	4
10	Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms 1992 ·Neurochemical Research ·Andrew Procter, Paul T. Francis, Gary C. Stratmann, David M. Bowen	57
11	Animal and drug modelling for Alzheimer synaptic pathology 1992 ·Progress in Neurobiology ·Paul T. Francis, Menelas N. Pangalos, David M. Bowen	30
12	Effect of Central Cholinergic Stimulation on Regional Cerebral Blood Flow in Alzheimer's Disease 1991 ·The British Journal of Psychiatry ·(unknown), David M. Bowen, Paul T. Francis, Pippa Tyrrell	22
13	Spermidine enhancement of [3H]MK-801 binding to the NMDA receptor complex in human cortical membranes 1990 ·European Journal of Pharmacology Molecular Pharmacology ·(unknown), David M. Bowen, Paul T. Francis, (unknown), A.J. Cross	20
14	Lack of Change in Neurochemical Markers During the Postepileptic Phase of Intrahippocampal Tetanus Toxin Syndrome in Rats 1990 ·Epilepsia ·Paul T. Francis, Stephen L. Lowe, David M. Bowen, John G. R. Jefferys	7
15	Tacrine, a Drug with Therapeutic Potential for Dementia: Post-Mortem Biochemical Evidence 1989 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Paul T. Francis, David M. Bowen	10
16	Pyramidal neuron loss and “glycine-site therapy”: A need for an animal model and study in late-life depression 1989 ·Neurobiology of Aging ·David M. Bowen, Paul T. Francis, (unknown), Menelas N. Pangalos, Andrew Procter, (unknown)	5
17	The N-methyl-d-aspartate receptor complex in Alzheimer's disease: reduced regulation by glycine but not zinc 1989 ·Brain Research ·Janet Steele, Alan M. Palmer, Gary C. Stratmann, David M. Bowen	36
18	Topographical distribution of neurochemical changes in Alzheimer's disease 1988 ·Journal of the Neurological Sciences ·Andrew Procter, Stephen L. Lowe, Alan M. Palmer, Paul T. Francis, Margaret M. Esiri, Gary C. Stratmann, A. Najlerahim, Ambrish J. Patel, C. Anthony Hunt, David M. Bowen	113
19	Possible neurotransmitter basis of behavioral changes in alzheimer's disease 1988 ·Annals of Neurology ·Alan M. Palmer, Gary C. Stratmann, Andrew Procter, David M. Bowen	168
20	Selective loss of serotonin recognition sites in the parietal cortex in Alzheimer's disease 1988 ·International Journal of Geriatric Psychiatry ·Andrew Procter, Derek N. Middlemiss, David M. Bowen	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact